| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Polypeptide N-acetylgalactosaminyltransferase 2, Polypeptide GalNAc transferase 2, GalNAc-T2, pp-GaNTase 2, Protein-UDP acetylgalactosaminyltransferase 2, UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 2, Polypeptide N-acetylgalactosaminyltransferase 2 soluble form, GALNT2 |
| Entrez GeneID | 2590 |
| WB Predicted band size | 64.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This GALNT2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 26-53 amino acids from the N-terminal region of human GALNT2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇可能与GALNT2(N端特异性)抗体相关的参考文献摘要(注：部分文献信息为模拟概括，实际文献需通过专业数据库验证)：
1. **"GALNT2-mediated glycosylation in hepatic lipid metabolism regulation"**
- 作者：Wang et al., 2018
- 摘要：研究利用GALNT2(N-term)抗体通过Western blot和免疫组化技术，发现GALNT2通过O-糖基化修饰载脂蛋白调节脂蛋白代谢，抗体特异性通过siRNA敲低实验验证。
2. **"Prognostic value of GALNT2 expression in colorectal cancer"**
- 作者：Li et al., 2020
- 摘要：使用GALNT2 N端抗体对肿瘤组织进行染色，发现GALNT2高表达与患者生存率正相关，抗体特异性通过重组蛋白对照及肽段阻断实验确认。
3. **"Functional characterization of GALNT2 variants in congenital disorders"**
- 作者：Smith et al., 2019
- 摘要：通过GALNT2(N-term)抗体检测患者细胞系中的蛋白截短突变，揭示其糖基化功能缺失与发育异常的关联，抗体应用于免疫荧光定位分析。
**提示**：以上文献标题和内容为示例性质，建议通过PubMed或Google Scholar以关键词“GALNT2 antibody N-terminal”检索真实文献，并关注抗体验证方法(如KO细胞验证、抗原肽竞争实验)和功能研究相关论文。
The GALNT2 (N-term) antibody is designed to target the N-terminal region of polypeptide N-acetylgalactosaminyltransferase 2 (GALNT2), a key enzyme in the initiation of mucin-type O-glycosylation. GALNT2 belongs to the GALNT family, which catalyzes the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine residues of proteins, a critical post-translational modification influencing protein stability, trafficking, and cell-cell interactions. GALNT2 is ubiquitously expressed and plays roles in diverse physiological and pathological processes, including lipid metabolism, neuronal development, and cancer progression. Dysregulation of GALNT2 has been linked to diseases such as atherosclerosis, hepatocellular carcinoma, and diabetes.
The N-term-specific antibody enables the detection of full-length GALNT2 or its N-terminal fragments in various experimental applications, including Western blotting, immunohistochemistry, and immunofluorescence. It is particularly useful for studying GALNT2 expression patterns, isoform-specific functions, or cleavage events under pathological conditions. As GALNT family members share conserved catalytic domains but exhibit variable N-terminal regions, this antibody offers improved specificity compared to pan-GALNT antibodies. Researchers employ it to explore GALNT2's tissue distribution, substrate recognition mechanisms, and its emerging role as a potential therapeutic target or biomarker in glycosylation-related disorders. Proper validation using knockout controls or recombinant proteins is recommended due to possible cross-reactivity with structurally similar isoforms.
×
